Ubs Group Ag Neuro Pace Inc Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Neuro Pace Inc stock. As of the latest transaction made, Ubs Group Ag holds 26,044 shares of NPCE stock, worth $276,066. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,044

Previous 6,910 276.9%

Holding current value

$276,066

Previous $77,000 315.58%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$10.04 - $14.94 $192,105 - $285,861	19,134 Added 276.9%	26,044 $320,000
Q4 2024 Feb 14, 2025	BUY	$5.9 - $11.93 $16,667 - $33,702	2,825 Added 69.16%	6,910 $77,000
Q3 2024 Nov 14, 2024	SELL	$6.65 - $8.46 $126 - $160	-19 Reduced 0.46%	4,085 $28,000
Q2 2024 Aug 13, 2024	BUY	$6.38 - $15.33 $15,337 - $36,853	2,404 Added 141.41%	4,104 $31,000
Q1 2024 May 13, 2024	BUY	$9.78 - $17.5 $16,626 - $29,750	1,700 New	1,700 $22,000
Q3 2023 Nov 09, 2023	BUY	$4.0 - $9.73 $220 - $535	55 New	55 $0
Q1 2023 May 12, 2023	BUY	$1.44 - $5.34 $1,542 - $5,719	1,071 Added 69.01%	2,623 $12,000
Q4 2022 Feb 08, 2023	SELL	$1.29 - $3.67 $801 - $2,279	-621 Reduced 28.58%	1,552 $2,000
Q3 2022 Nov 10, 2022	BUY	$3.1 - $5.98 $6,736 - $12,994	2,173 New	2,173 $8,000
Q2 2022 Aug 10, 2022	SELL	$4.95 - $8.7 $499 - $878	-101 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$7.06 - $11.57 $25,430 - $41,675	-3,602 Reduced 97.27%	101 $1,000
Q4 2021 Feb 14, 2022	BUY	$8.63 - $17.36 $31,956 - $64,284	3,703 New	3,703 $38,000
Q3 2021 Nov 15, 2021	SELL	$15.85 - $25.07 $40,623 - $64,254	-2,563 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$19.03 - $26.5 $48,773 - $67,919	2,563 New	2,563 $61,000

Others Institutions Holding NPCE

# of Institutions

Shares Held

29.9M

Call Options Held

1.8K

Put Options Held

300

View Full List

About NeuroPace Inc

Ticker NPCE
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 24,846,900
Market Cap $263M
Description
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...

More about NPCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account